Details
Stereochemistry | RACEMIC |
Molecular Formula | C15H23NO3 |
Molecular Weight | 265.348 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)NCC(O)COC1=C(OCC=C)C=CC=C1
InChI
InChIKey=CEMAWMOMDPGJMB-UHFFFAOYSA-N
InChI=1S/C15H23NO3/c1-4-9-18-14-7-5-6-8-15(14)19-11-13(17)10-16-12(2)3/h4-8,12-13,16-17H,1,9-11H2,2-3H3
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6356863/Curator's Comment: Description was created based on several sources, including:
https://www.medicines.org.uk/emc/PIL.27982.latest.pdf
https://www.ncbi.nlm.nih.gov/pubmed/6344036
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6356863/
Curator's Comment: Description was created based on several sources, including:
https://www.medicines.org.uk/emc/PIL.27982.latest.pdf
https://www.ncbi.nlm.nih.gov/pubmed/6344036
Oxprenolol is clinically a well-established beta blocker that shares with other members of this group the ability to control a variety of disorders, in particular, hypertension and angina. Pharmacologically it is a nonselective beta blocker that possesses partial agonist activity (intrinsic sympathomimetic activity). Pharmacokinetically, oxprenolol behaves as a moderately lipophilic agent. Oxprenolol undergoes first pass metabolism with only 30% of an oral dose reaching the systemic circulation. The drug is approximately 80% protein bound and is eliminated primarily by glucuronidation in the liver. Less than 4% of oxprenolol is excreted unchanged in the urine. Oxprenolol may reduce the heart rate and prolong the effective and functional atrioventricular nodal refractory period. Oxprenolol has less negative inotropic and chronotropic effects than propranolol. Plasma renin activity is reduced; however, changes in plasma aldosterone level are not significant. Long term metabolic effects require further study. Chest pain (angina), high blood pressure (hypertension), irregular heart beats and anxiety are indications for Oxprenolol usage. To date Oxprenolol is discontinued by FDA.
Originator
Sources: Drug Discovery: A History. W. Sneader. John Wiley & Sons, 2005 pp 468
Curator's Comment: https://books.google.ru/books?id=Cb6BOkj9fK4C&pg=PA193&lpg=PA193&dq=Oxprenolol+first+discovered&source=bl&ots=NOemB0BehV&sig=ozflVDgEzprG_g-hgUfTYdJeoPw&hl=ru&sa=X&ved=0ahUKEwiv1pLbl6jQAhUHiCwKHTGTDusQ6AEIIzAB#v=onepage&q=Oxprenolol&f=false
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2094118 Sources: http://www.genome.jp/dbget-bin/www_bget?dr:D08318 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TRASICOR Approved UseTrasicor is used to treat high blood pressure and to reduce or prevent chest pain (angina). It is also used to treat some heart disorders such as irregular heart beat and to relieve the symptoms of anxiety. Launch Date4.41331188E11 |
|||
Primary | TRASICOR Approved UseTrasicor is used to treat high blood pressure and to reduce or prevent chest pain (angina). It is also used to treat some heart disorders such as irregular heart beat and to relieve the symptoms of anxiety. Launch Date4.41331188E11 |
|||
Primary | TRASICOR Approved UseTrasicor is used to treat high blood pressure and to reduce or prevent chest pain (angina). It is also used to treat some heart disorders such as irregular heart beat and to relieve the symptoms of anxiety. Launch Date4.41331188E11 |
|||
Primary | TRASICOR Approved UseTrasicor is used to treat high blood pressure and to reduce or prevent chest pain (angina). It is also used to treat some heart disorders such as irregular heart beat and to relieve the symptoms of anxiety. Launch Date4.41331188E11 |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
60.7 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7712670 |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
(S)-(-)-OXPRENOLOL blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
73.1 μg × min/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7712670 |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
(R)-(+)-OXPRENOLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
108.4 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7712670 |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
(S)-(-)-OXPRENOLOL blood | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
111.6 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7712670 |
80 mg single, oral dose: 80 mg route of administration: Oral experiment type: SINGLE co-administered: |
(R)-(+)-OXPRENOLOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
20 mg single, intravenous Highest studied dose |
healthy, 21 - 29 years n = 6 Health Status: healthy Age Group: 21 - 29 years Sex: M+F Population Size: 6 Sources: |
|
480 mg 1 times / day multiple, oral Studied dose Dose: 480 mg, 1 times / day Route: oral Route: multiple Dose: 480 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Disc. AE: Headache... AEs leading to discontinuation/dose reduction: Headache (severe, 1 patient) Sources: |
160 mg 1 times / day multiple, oral (starting) Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Disc. AE: Weakness, Headache... AEs leading to discontinuation/dose reduction: Weakness (6 patients) Sources: Headache (6 patients) Malaise (6 patients) Fatigue (6 patients) Bad dreams (6 patients) Fluid retention (1 patient) |
160 mg 2 times / day multiple, oral Dose: 160 mg, 2 times / day Route: oral Route: multiple Dose: 160 mg, 2 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Disc. AE: Weakness, Headache... AEs leading to discontinuation/dose reduction: Weakness (2 patients) Sources: Headache (2 patients) Malaise (2 patients) Fatigue (2 patients) Bad dreams (2 patients) Fluid retention (1 patient) |
160 mg 3 times / day multiple, oral Studied dose Dose: 160 mg, 3 times / day Route: oral Route: multiple Dose: 160 mg, 3 times / day Sources: |
unhealthy n = 1 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Headache | severe, 1 patient Disc. AE |
480 mg 1 times / day multiple, oral Studied dose Dose: 480 mg, 1 times / day Route: oral Route: multiple Dose: 480 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Fluid retention | 1 patient Disc. AE |
160 mg 1 times / day multiple, oral (starting) Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Bad dreams | 6 patients Disc. AE |
160 mg 1 times / day multiple, oral (starting) Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Fatigue | 6 patients Disc. AE |
160 mg 1 times / day multiple, oral (starting) Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Headache | 6 patients Disc. AE |
160 mg 1 times / day multiple, oral (starting) Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Malaise | 6 patients Disc. AE |
160 mg 1 times / day multiple, oral (starting) Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Weakness | 6 patients Disc. AE |
160 mg 1 times / day multiple, oral (starting) Dose: 160 mg, 1 times / day Route: oral Route: multiple Dose: 160 mg, 1 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Fluid retention | 1 patient Disc. AE |
160 mg 2 times / day multiple, oral Dose: 160 mg, 2 times / day Route: oral Route: multiple Dose: 160 mg, 2 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Bad dreams | 2 patients Disc. AE |
160 mg 2 times / day multiple, oral Dose: 160 mg, 2 times / day Route: oral Route: multiple Dose: 160 mg, 2 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Fatigue | 2 patients Disc. AE |
160 mg 2 times / day multiple, oral Dose: 160 mg, 2 times / day Route: oral Route: multiple Dose: 160 mg, 2 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Headache | 2 patients Disc. AE |
160 mg 2 times / day multiple, oral Dose: 160 mg, 2 times / day Route: oral Route: multiple Dose: 160 mg, 2 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Malaise | 2 patients Disc. AE |
160 mg 2 times / day multiple, oral Dose: 160 mg, 2 times / day Route: oral Route: multiple Dose: 160 mg, 2 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
Weakness | 2 patients Disc. AE |
160 mg 2 times / day multiple, oral Dose: 160 mg, 2 times / day Route: oral Route: multiple Dose: 160 mg, 2 times / day Sources: |
unhealthy, 22 - 70 years n = 58 Health Status: unhealthy Condition: Hypertensive patients Age Group: 22 - 70 years Sex: M+F Population Size: 58 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Severe hypertension produced by interaction of phenylpropanolamine with methyldopa and oxprenolol. | 1976 Jul 31 |
|
[The role of reduction of the heart rate in the favorable effect of the beta blockers on myocardial ischemia due to isoprenalin in patients with angina pectoris]. | 1977 Nov 5 |
|
Mediation of renin release in essential hypertension by alpha-adrenoreceptors. | 1981 Nov-Dec |
|
Beta-adrenoreceptor antagonists and diplopia. | 1982 Oct 9 |
|
Some functional changes in experimentally induced cardiac overload. | 1983 |
|
Predictors of blood pressure increases after withdrawal of antihypertensive therapy. | 1985 Dec |
|
Interference by sulphinpyrazone with the antihypertensive effects of oxprenolol. | 1986 |
|
Comparison of pharmacokinetic properties of beta-adrenoceptor blocking drugs. | 1987 Dec |
|
Beta-blockade in the primary prevention of coronary heart disease in hypertensive patients. Review of present evidence. | 1991 Dec |
Patents
Sample Use Guides
Chest pain (angina): 80-160 mg a day taken in 2 to 3 doses. The maximum daily dose is 320 mg.
High blood pressure (hypertension): 80-160 mg a day given in 2 to 3 doses. The maximum daily dose is 320 mg.
Irregular heart beats: 20-80 mg taken 2 or 3 times a day. The maximum daily dose is 240 mg.
Anxiety: The starting dose is 40 mg taken twice a day. A single dose of Trasicor (40-80 mg) may be taken for anxiety during a specific stressful situation.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6152393
Oxprenolol had biphasic actions on the rat sarcolemmal Ca2+ pump activities; the lower concentrations (1 and 10 microM) were stimulatory, but the higher concentrations (100 and 1000 microM) were inhibitory.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C07BA02
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
||
|
WHO-VATC |
QC07CA02
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
||
|
WHO-ATC |
C07AA02
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
||
|
NCI_THESAURUS |
C29576
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
||
|
WHO-VATC |
QC07BA02
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
||
|
WHO-ATC |
C07CA02
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
||
|
WHO-VATC |
QC07AA02
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
4631
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
PRIMARY | |||
|
7801
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
PRIMARY | RxNorm | ||
|
SUB09555MIG
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
PRIMARY | |||
|
DB01580
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
PRIMARY | |||
|
C66276
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
PRIMARY | |||
|
D010096
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
PRIMARY | |||
|
CHEMBL546
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
PRIMARY | |||
|
2027
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
PRIMARY | |||
|
6452-71-7
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
PRIMARY | |||
|
229-257-9
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
PRIMARY | |||
|
7255
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
PRIMARY | |||
|
m8321
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
PRIMARY | Merck Index | ||
|
DTXSID1043835
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
PRIMARY | |||
|
100000083299
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
PRIMARY | |||
|
519MXN9YZR
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
PRIMARY | |||
|
2506
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
PRIMARY | |||
|
OXPRENOLOL
Created by
admin on Fri Dec 15 19:00:27 UTC 2023 , Edited by admin on Fri Dec 15 19:00:27 UTC 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)